
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
For the past few months, I have been a part of an arbitration panel of physicians, hired by an organization that gives independent opinions concerning claims for reimbursement for medical providers, pre-authorization issues and quality of care issues.

